Antiplasmodial and antitrypanosomal activity of new esters and ethers of 4-dialkylaminobicyclo[2.2.2]octan-2-ols

European Journal of Pharmaceutical Sciences

Volumn 28, Issue 5, 2006, Pages 361-368

  Weis, Robert ^a   Schlapper, Christian ^a   Brun, Reto ^b   Kaiser, Marcel ^b   Seebacher, Werner ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

Author keywords

4 Aminobicyclo 2.2.2 octane derivatives; Bicyclooctylesters; Bicyclooctylethers; In vitro assays; Plasmodium falciparum; Trypanosoma brucei rhodesiense

Indexed keywords

2 BENZHYDRYLOXY 6,7 DIPHENYLBICYCLO[2.2.2]OCTANE 4 PIPERIDINE; 2 BENZHYDRYLOXY 6,7 DIPHENYLBICYCLO[2.2.2]OCTANE 4 PYRROLIDINE; 2 BENZHYDRYLOXY N,N DIMETHYL 6,7 DIPHENYLBICYCLO[2.2.2]OCTAN 4 AMINE; 2 BENZYLOXY 6,7 DIPHENYLBICYCLO[2.2.2]OCTANE 4 PIPERIDINE; 2 BENZYLOXY 6,7 DIPHENYLBICYCLO[2.2.2]OCTANE 4 PYRROLIDINE; 2 BIS(4 CHLOROPHENYL)METHOXY 6,7 DIPHENYLBICYCLO[2.2.2]OCTANE 4 PIPERIDINE; 2 BIS(4 CHLOROPHENYL)METHOXY 6,7 DIPHENYLBICYCLO[2.2.2]OCTANE 4 PYRROLIDINE; 2 BIS(4 CHLOROPHENYL)METHOXY N,N DIMETHYL 6,7 DIPHENYLBICYCLO[2.2.2]OCTAN 4 AMINE; 4 CHLOROBENZOIC ACID; 4 DIMETHYLAMINO 6,7 DIPHENYLBICYCLO[2.2.2]OCTAN 2 YL 4 CHLOROBENZOATE; 4 DIMETHYLAMINO 6,7 DIPHENYLBICYCLO[2.2.2]OCTAN 2 YLDIPHENYLACETATE; 4 DIMETHYLAMINO 6,7 DIPHENYLBICYCLO[2.2.2]OCTAN 2 YLPIVALATE; 6,7 DIPHENYL 4 PIPERIDINOBICYCLO[2.2.2]OCTAN 2 YL 4 CHLOROBENZOATE; 6,7 DIPHENYL 4 PIPERIDINOBICYCLO[2.2.2]OCTAN 2 YLDIPHENYLACETATE; 6,7 DIPHENYL 4 PIPERIDINOBICYCLO[2.2.2]OCTAN 2 YLPIVALATE; 6,7 DIPHENYL 4 PYRROLIDINOBICYCLO[2.2.2]OCTAN 2 YL 4 CHLOROBENZOATE; 6,7 DIPHENYL 4 PYRROLIDINOBICYCLO[2.2.2]OCTAN 2 YLDIPHENYLACETATE; 6,7 DIPHENYL 4 PYRROLIDINOBICYCLO[2.2.2]OCTAN 2 YLPIVALATE; ANTITRYPANOSOMAL AGENT; BENZHYDRYL ETHER; CHLOROQUINE; ESTER DERIVATIVE; ETHER DERIVATIVE; PIVALATE; PYRIMETHAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CYTOTOXICITY; DRUG ACTIVITY; IC 50; IN VITRO STUDY; LIPOPHILICITY; MALARIA; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; TRYPANOSOMA RHODESIENSE; TRYPANOSOMIASIS;

ANIMALS; ANTIMALARIALS; BICYCLO COMPOUNDS; ESTERS; MAGNETIC RESONANCE SPECTROSCOPY; PLASMODIUM FALCIPARUM; SPECTROPHOTOMETRY, ULTRAVIOLET; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI;

EID: 33745836367     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.04.003     Document Type: Article

References (19)

1. Amexo M., Tolhurst R., Barnish G., and Bates I. Malaria misdiagnosis: effects on the poor and vulnerable. Lancet 364 (2004) 1896-1898
2. Anene B.M., Onah D.N., and Nawa Y. Drug resistance in pathogenic African trypanosomes: what hopes for the future?. Vet. Parasitol. 96 (2001) 83-100
3. Barrett M.P. The fall and rise of sleeping sickness. Lancet 353 (1999) 1113-1114
4. Berger B.J., Carter N.S., and Fairlamb A.H. Characterisation of pentamidine-resistant Trypanosoma brucei brucei. Mol. Biochem. Parasitol. 69 (1995) 289-298
5. Hoet S., Opperdoes F., Brun R., and Quetin-Leclercq J. Natural products active against African trypanosomes: a step towards new drugs. Nat. Prod. Rep. 21 (2004) 353-364
6. Hyde J.E. Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect. 4 (2002) 165-174
7. Loutan L. Malaria: still a threat to travellers. Int. J. Antimicrob. Agents 21 (2003) 158-163
8. Matovu E., Seebeck T., Enyaru J.C.K., and Kaminsky R. Drug resistance in Trypanosoma brucei spp., the causative agents of sleeping sickness in man and nagana in cattle. Microbes Infect. 3 (2001) 763-770
9. Meshnick S.R. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. 32 (2002) 1655-1660
10. Seebacher W., Brun R., Saf R., Kröpfl D., and Weis R. New derivatives of 4-aminobicyclo[2.2.2]octanones and -ols as potential antiprotozoals. Monatsh. Chem. 135 (2004) 313-322
11. Seebacher W., Brun R., and Weis R. New 4-aminobicyclo[2.2.2]octane derivatives and their activities against Plasmodium falciparum and Trypanosoma b. rhodesiense. Eur. J. Pharm. Sci. 21 (2004) 225-233
12. Seebacher W., Brun R., Kaiser M., Saf R., and Weis R. Synthesis and evaluation of the antitrypanosomal and antiplasmodial activities of new 4-aminobicyclo[2.2.2]octane derivatives. Eur. J. Med. Chem. 40 (2005) 888-896
13. Seebacher W., Schlapper C., Brun R., Kaiser M., Saf R., and Weis R. Antiprotozoal activities of new bicyclo[2.2.2]octan-2-imines and esters of bicyclo[2.2.2]octan-2-ols. Eur. J. Pharm. Sci. 24 (2005) 281-289
14. Tanser F.C., and le Suer D. The application of geographical information systems to public health problems in Africa. Int. J. Health Geogr. 1 (2002) 4
15. Weis R., Schweiger K., Seebacher W., and Belaj F. One-pot synthesis of 4-aminobicyclo[2.2.2]octan-2-ones. Tetrahedron 54 (1998) 14015-14022
16. Weis R., Brun R., Saf R., and Seebacher W. 4-Aminobicyclo[2.2.2]octanone derivatives with antiprotozoal activities. Monatsh. Chem. 134 (2003) 1019-1026
17. Wickware P. Resurrecting the resurrection drug. Nat. Med. 8 (2002) 908-909
18. Winstanley P.A., Ward S.A., and Snow R.W. Clinical status and implications of antimalarial drug resistance. Microbes Infect. 4 (2002) 157-164
19. Wongsrichanalai C., Pickard A.L., Wernsdorfer E.H., and Meshnik S.R. Epidemiology of drug resistant malaria. Lancet Infect. Dis. 2 (2002) 209-218